NCT04945772: An ongoing trial by Nanoscope Therapeutics Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 2 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04945772 |
|---|---|
| Title | A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 13, 2021 |
| Completion date | Feb. 27, 2023 |
| Required reporting date | Feb. 27, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |